Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuigui Cataplasm, also known as Shuigui Babugao, is a traditional Chinese medicine (TCM) hospital-made preparation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine. It is specifically formulated for the external treatment of liver cirrhosis and associated ascites. The preparation is typically applied topically to the Shenque point (umbilicus), a practice known as umbilical therapy, to facilitate the transdermal absorption of its active constituents. The formulation is based on TCM principles of nourishing yin, softening hardness, and promoting diuresis to resolve fluid accumulation. Clinical and experimental studies suggest that the cataplasm helps reduce abdominal circumference and improve liver function by modulating fluid metabolism and potentially regulating the expression of water channel proteins. It is used as an adjuvant therapy alongside conventional Western medical treatments for portal hypertension and cirrhotic complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shuigui Cataplasm.